Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas
Authors
Keywords
Glioblastoma, CD133, CD34, Vascular endothelial growth factor (VEGF), Isocitrate dehydrogenase1 (IDH1)
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 115, Issue 3, Pages 333-341
Publisher
Springer Nature
Online
2013-10-16
DOI
10.1007/s11060-013-1234-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Neoplastic cells are a rare component in human glioblastoma microvasculature
- (2015) Fausto J. Rodriguez et al. Oncotarget
- IDH1Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA-Mediated Clamping PCR
- (2012) Dakeun Lee et al. BRAIN PATHOLOGY
- IDH mutations in acute myeloid leukemia
- (2012) Dinesh Rakheja et al. HUMAN PATHOLOGY
- Prognostic Impact of CD133 mRNA Expression in 48 Glioblastoma Patients Treated with Concomitant Radiochemotherapy: A Prospective Patient Cohort at a Single Institution
- (2011) Philippe Metellus et al. ANNALS OF SURGICAL ONCOLOGY
- Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
- (2011) Shingo Takano et al. Brain Tumor Pathology
- Inconsistent Immunohistochemical Expression Patterns of Four Different CD133 Antibody Clones in Glioblastoma
- (2011) Simon K. Hermansen et al. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
- IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients
- (2011) Philippe Metellus et al. JOURNAL OF NEURO-ONCOLOGY
- Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
- (2011) Hee Joung Kim et al. LUNG CANCER
- Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas
- (2010) Juan L Garcia et al. BMC CANCER
- Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis
- (2010) Roberto Pallini et al. CANCER
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Detection of Low-Level KRAS Mutations Using PNA-Mediated Asymmetric PCR Clamping and Melting Curve Analysis with Unlabeled Probes
- (2010) Ji Eun Oh et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Biology of glioma cancer stem cells
- (2009) Deric M. Park et al. MOLECULES AND CELLS
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns
- (2009) Yaojiong Wu et al. STEM CELLS AND DEVELOPMENT
- Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
- (2008) R. Pallini et al. CLINICAL CANCER RESEARCH
- Stem Cell Marker CD133 Affects Clinical Outcome in Glioma Patients
- (2008) F. Zeppernick et al. CLINICAL CANCER RESEARCH
- Presence of pluripotent CD133+ cells correlates with malignancy of gliomas
- (2008) Niklas Thon et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- High-grade glioma before and after treatment with radiation and Avastin: Initial observations
- (2008) Ingeborg Fischer et al. NEURO-ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started